Extracellular Vesicles and Endothelial Function in Transgender Subjects
- Conditions
- Transgenderism
- Interventions
- Drug: gender affirming hormonal treatment in transgender menDrug: gender affirming hormonal treatment in transgender women
- Registration Number
- NCT04971447
- Lead Sponsor
- Central Hospital, Nancy, France
- Brief Summary
Cardiovascular diseases are the leading cause of mortality. In women, the prevalence of cardiovascular diseases is lower and the presentation of coronary events often atypical. The lack of evidence is related in part to the methodology of studies not considering sex as an essential biological variable. Hormonal treatment is prescribed in transgender subjects to promote the development of sexual characteristics of the desired sex. Early cardiovascular effects of hormonal treatment have been reported in transgender men, while long-term mortality is higher in transgender women. The aim of this project is to study the effects of gender affirming hormonal treatment on arterial stiffness in young transgender subjects followed at the University Hospital of Nancy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 136
- Trasgender subject demanding gender affirming hormonal therapy
- Previous hormonal therapy
- Pregnancy
- Chronic disease
- Cancer
- Obesity
- Drug abuse
- Alcohol
- Tabac
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Group: transgender men gender affirming hormonal treatment in transgender men - Group: transgender women gender affirming hormonal treatment in transgender women -
- Primary Outcome Measures
Name Time Method pulse wave velocity 24 months measurement of arterial stiffness
- Secondary Outcome Measures
Name Time Method